HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK And Novartis Hit With $3m Fine In Australia For Misleading Voltaren Claims

Executive Summary

Marketing Voltaren Osteo Gel as more effective for treating osteoarthritis than the identically formulated Voltaren Emugel has landed GSK and Novartis with a substantial fine for breaching Australian Consumer Law.

You may also be interested in...



GSK Admits Voltaren Marketing Misled Australian Consumers, Now Facing Financial Penalty

GSK has admitted misleading Australian consumers with the marketing of its Voltaren range by claiming Osteo Gel was specifically formulated for treating osteoarthritis conditions, and was more effective than Emulgel to treat those conditions, when the two products were identically formulated. While a change to Osteo Gel's packaging has since satisfied Australia's Federal Court, GSK is still facing a financial penalty for its earlier conduct.

P&G Given Green Light To Offload Haliborange Supplements

P&G's decision to offload its Haliborange children's supplement line will not lead to reduced competition in the UK market, according to the regulator.

Light In The Dark For Troubled GNC As It Wins Trademark Dispute

GNC has won a long running dispute over the use of its "GNC Live Well" trademark in Europe after a challenge by Lithuanian pharmacy retailer Euroapotheca was rejected by the European General Court.

Topics

Related Companies

UsernamePublicRestriction

Register

SC100339

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel